Antibody-drug conjugates (ADCs) are a promising class of cancer biopharmaceuticals that
exploit the specificity of a monoclonal antibody (mAb) to selectively deliver highly cytotoxic …

Human epidermal growth factor receptor 2 (HER2) regulates cell mitosis, proliferation, and
apoptosis. Trastuzumab is a HER2-targeted monoclonal antibody (mAB), which can prolong …

The targeted delivery of potent cytotoxic molecules into cancer cells is considered a
promising anticancer strategy. The design of clinically effective antibody–drug conjugates …

Background Current treatment options for human epidermal growth factor receptor 2 (HER2)‐
overexpressing gastric cancer at third‐line have shown limited clinical benefit. Further, there …

Abstract Background Disitamab vedotin (DV; RC48‐ADC) is an antibody‐drug conjugate
comprising a human epidermal growth factor receptor 2 (HER2)‐directed antibody, linker …

Ovarian cancer is a highly lethal disease that affects women. Early diagnosis and treatment
of women with early-stage disease improve the probability of survival. Unfortunately, the …

HER2-targeted immunotherapy consists of monoclonal antibodies (eg trastuzumab,
pertuzumab), bispecific antibodies (eg MM-111, ertumaxomab) and activated T cells armed …

Background Ovarian cancer (OC) is a prevalent malignancy in the female reproductive
system, and developing effective targeted therapies for this disease remains challenging …

Antibody-drug conjugates (ADCs) combining potent cytotoxicity of small-molecule drugs with
the selectivity and excellent pharmacokinetic profile of monoclonal antibody (mAb) are …

Trastuzumab emtansine (T‐DM 1), an antibody–drug conjugate (ADC) consisting of human
epidermal growth factor receptor 2 (HER 2)‐targeted mA b trastuzumab linked to …